Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1068MR)

This product GTTS-WQ1068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1068MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4014MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ8492MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ4099MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ749MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ6689MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ11367MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ11174MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ170MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW